Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Biocircuits ends its year of seclusion

Biocircuits Corp. is coming out of its self-imposed quiet period, which began more than a year ago when the company decided to redesign its immunodiagnostic testing system. That process is nearing completion, and the Sunnyvale, Calif., company anticipates submitting a 510(k) in mid-June for the system and initial two assays, T4 and T Uptake, for determining thyroid dysfunction. The 510(k) will trigger an $8.7 million funding round.

BIOC's retrenchment began in late 1993, when the company found a

Read the full 773 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers